Background: The introduction of adjuvant imatinib in gastrointestinal stromal tumors (GISTs) raised debate over the accuracy of National Institutes of Health risk criteria and the significance of other prognostic factors in GIST. Methods: Tumor aggressiveness and other clinicopathological factors influencing disease-free survival (DFS) were assessed in 335 patients with primary resectable CD117-immunopositive GISTs (median follow-up, 31 months after primary tumor resection) from a prospectively collected tumor registry. Results: Overall median DFS was 37 months, and estimated 5-year DFS was 37.8 %. In univariate analysis, high or intermediate risk group (P < .000001), mitotic index >5/50 high-power field (P < .00001), primary tumor size >5 cm (P 5/50 high-power field (P = .004), primary tumor size >5 cm (P = .001), male sex (P = .003), R1 resection/tumor rupture (P = .04), and nongastric primary tumor location (P = .02), and for model 2 were high/intermediate risk primary tumor (P
CITATION STYLE
Rutkowski, P., Nowecki, Z. I., Michej, W., Dębiec-Rychter, M., Woźniak, A., Limon, J., … Ruka, W. (2007). Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Annals of Surgical Oncology, 14(7), 2018–2027. https://doi.org/10.1245/s10434-007-9377-9
Mendeley helps you to discover research relevant for your work.